​

Funding Round

Series C - Syndax Pharmaceuticals

Series C - Syndax Pharmaceuticals

Investment Firm

Overview

Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.

Announced Date

Aug 24, 2015

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Fidelity

Fidelity

Fidelity is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed firm.

Delos Capital

Delos Capital

Delos Capital is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity firm.

Participant Investors

13

Investor Name
Participant InvestorEcoR1 Capital
Participant InvestorOrbiMed
Participant InvestorMPM Capital
Participant InvestorDomain Associates
Participant InvestorFidelity

Round Details and Background

Syndax Pharmaceuticals raised $80000000 on 2015-08-24 in Series C

Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.

Company Funding History

15

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 13, 2014
Venture Round - Syndax Pharmaceuticals
-1.7M
Apr 05, 2010
Debt Financing - Syndax Pharmaceuticals
-6.0M
Aug 27, 2013
Series B - Syndax Pharmaceuticals
4-26.6M
Mar 16, 2010
Series A - Syndax Pharmaceuticals
5-9.0M

Recent Activity

There is no recent news or activity for this profile.